Propel Funeral Partners Stock (OTC: PFPLF)

Propel Funeral Partners (OTC:PFPLF) Stock, Quote.Headers.trade-ideas

Propel Funeral Partners Ltd is an Australia-based company engaged in the provision of death care services. The company owns funeral homes, cremation facilities, cemeteries, and related infrastructure in Queensland, New South Wales, Victoria, Tasmania, South Australia, Western Australia, Australian Capital Territory, and New Zealand. It offers a range of services and products across death care such as tailored to personal, religious, or ethnic preferences. The Group is organized into two geographic segments, Australian operations, and New Zealand operations, both of which operate in the death care-related services industry. The Group generates the majority of its revenue from the Australia operations.

PROPEL FUNERAL PRTNES LTD by PROPEL FUNERAL PARTNERS LTD.

Propel Funeral Partners Ltd

Needham analyst Quinn Bolton maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and lowers the price target from $74 to $54.

News

Price Target

Analyst Ratings

SMTC

Needham Maintains Buy on Semtech, Lowers Price Target to $54

Biotech

General

BRTX

BioRestorative Therapies, Inc. Highlights Presentation Or Preliminary BRTX-100 Data At Orthopaedic Research Society

These projects are expected to begin in 2025 with varying completion dates extending through 2026. These awards further reinforce Orion's position as a leader in specialized Marine and Concrete construction.

Contracts

Orion Group Bags New Marine And Concrete Awards For Total Value Of Approximately $211.7M

Benchmark analyst David Williams reiterates Belden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) with a Buy and maintains $130 price target.

Reiteration

Benchmark Reiterates Buy on Belden, Maintains $130 Price Target

INMB

INmune Bio Plans To Submit FDA Biologics License Application Seeking Approval Of CORDStrom For Recessive Dystrophic Epidermolysis Bullosa

Lucid Motors Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) CEO Peter Rawlinson envisions the EV company being more of a supplier than a carmaker in the future, similar to the ambitions of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk.
What Happened: In an interview <a href="https://insideevs.com/news/750043/lucid-ceo-supplier-peter-rawlinson/">with</a> InsideEVs at the BloombergNEF Summit in San Francisco, Rawlinson said that he would prefer 20% of Lucid&#8217;s future business to be about making cars and the remaining 80% about licensing.
&#8220;Because the vision I have for Lucid is: Just as there's an Intel inside your laptop, there's a Lucid inside a Honda or a Toyota,&#8221; he reportedly said without specifying a timeline for when he envisions it. 
Lucid makes cars as a means of showcasing and marketing its products, he said. The company intends to make a million cars per year by the early 2030s. 
British carmaker <a href="https://www.benzinga.com/news/24/08/40182315/lucids-partnership-with-aston-martin-unaffected-by-delays-in-british-carmakers-ev-timeline-were-soli">Aston Martin signed a deal with Lucid in 2023</a> for technology including electric powertrains and battery systems. However, Aston Martin is yet to launch a battery electric car. 
In the future, however, Rawlinson expects to license Lucid&#8217;s tech to rivals, so they make their components.
&#8220;You flash your Microsoft Office—ka-chunk—Bill Gates gets his royalty, doesn't he? And I want to be like that,&#8221; Rawlinson reportedly said. 
However, the CEO also clarified that this is merely his vision for the company and there is no guarantee that it will happen. 
Giant Paves The Way: Musk, also, likewise, is attempting to make Tesla more than a carmaker. The billionaire CEO has often reiterated that Tesla is not a carmaker but an AI and robotics company with efforts to build humanoid robots and develop autonomous driving technology. Tesla is also attempting to license its full self-driving driver assistance technology <a href="https://www.benzinga.com/24/12/42452794/bmw-takes-down-appreciation-for-version-13-of-teslas-fsd-too-bad-says-musk">to rival automakers.</a>
However, automotive revenue accounted for <a href="https://www.benzinga.com/tech/25/01/43327268/tesla-expects-50-surge-in-energy-storage-deployments-for-2025-after-segment-revenue-doubles-in-q4">nearly 79% of Tesla&#8217;s overall revenue</a> in 2024. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43577187/spacex-to-land-falcon-9-first-stage-off-the-coast-of-the-bahamas-later-this-month" target="_blank" rel="noreferrer noopener">Elon Musk's SpaceX To Land Falcon 9 First Stage Off The Coast Of The Bahamas Later This Month</a></li>
</ul>
Photo courtesy: Lucid

Tech

LCID

TSLA

Peter Rawlinson Wants Lucid To Be The Intel Of EVs: 'You Flash Your Microsoft Office… Bill Gates Gets His Royalty… I Want To Be Like That'

Health Care

NKTR

The FDA Has Granted Fast Track Designation To Nektar Therapeutics' Rezpegaldesleukin For Adult And Pediatric Patients 12 Years Of Age And Older With Moderate-to-severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled With Topical Prescription Therapies Or When Those Therapies Are Not Advisable

Guidance

TSEM

Tower Semiconductor Expects Q1 Revenues To Be $358M, With An Upward Or Downward Range Of 5%; Est $357.5M

Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $9.02 million which missed the analyst consensus estimate of $15.99 million by 43.60 percent. This is a 42.05 percent decrease over sales of $15.56 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

ROIV

Roivant Sciences Q3 Adj $(0.20) Beats $(0.28) Estimate, Sales $9.02M Miss $15.99M Estimate

Benchmark analyst David Williams reiterates MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Buy and maintains $160 price target.

MTSI

Benchmark Reiterates Buy on MACOM Technology Solns, Maintains $160 Price Target

In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This represents a significant step forward as it's the first time the committee has formally recognized ctDNA as being prognostic. The guidelines remain cautious about ctDNA for surveillance, as expected. The NCCN finalized these updates before data from the phase III CALGB (Alliance) / SWOG 80702 study were presented at ASCO GI in January, supporting the predictive nature of Signatera in the adjuvant setting.

NTRA

Natera Commented On Recent Updates By The NCCN On Circulating Tumor DNA Molecular Residual Disease Testing In The Clinical Practice Guidelines In Oncology For Colon Cancer, Rectal Cancer, And Merkel Cell Carcinoma

TD will continue to have a business relationship with Schwab through the Insured Deposit Account (IDA) Agreement.
TD currently holds 184.7 million shares of Schwab's common stock, representing 10.1% economic ownership. Schwab has agreed to repurchase $1.5 billion of its shares from TD conditional on completion of the offering.

Offerings

Buybacks

SCHW

TD Bank Group Intends To Sell Its Entire Equity Investment In Charles Schwab Through Registered Offering And Share Repurchase By Schwab

WIIM

MNDY

Monday.com share are trading higher after the company reported better-than-expected Q4 financial results and Q1 revenue outlook.

D. Boral Capital analyst Jason Kolbert downgrades Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) from Buy to Hold.

Downgrades

ANVS

D. Boral Capital Downgrades Annovis Bio to Hold

Cyngn &nbsp;announced Friday that it has secured $33 million in funding. This funding positions the company to accelerate its growth and deliver on its mission to proliferate industrial autonomous vehicles.

REKR

Rekor Systems Entered $25M At-Market Issuance Sales Agreement With Northland Securities

This represents approximately 5.7% of its issued and outstanding common shares and its public float as af October 31, 2024. TD will file a notice of intention with the TSX in this regard.

TD Bank Group Reveals Intention To Purchase For Cancellation Up To 100M Of Its Common Shares

Financial Outlook:
For the first quarter of fiscal year 2025, monday.com currently expects:
●&nbsp;&nbsp;&nbsp; Total revenue of $274 million to $276 million, representing year-over-year growth of 26% to 27%.
●&nbsp;&nbsp;&nbsp; Non-GAAP operating income of $25 million to $27 million and operating margin of 9% to 10%.
For the full year 2025, monday.com currently expects:
●&nbsp;&nbsp;&nbsp; Total revenue of $1,208 million to $1,221 million, representing year-over-year growth of 24% to 26%, and assumes a negative FX impact of 100 to 200 basis points.
●&nbsp;&nbsp;&nbsp; Non-GAAP operating income of $134 million to $142 million and operating margin of 11% to 12%.
●&nbsp;&nbsp;&nbsp; Free cash flow of $300 million to $308 million and free cash flow margin of approximately 25%.

Monday.com FY25 Revenue Outlook $1.21B-$1.22B Vs. $1.21B Estimate

Fiscal Year 2025 Outlook
The table below provides updated guidance for sales growth and earnings per share for fiscal 2025.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Updated Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported sales midpoint</td>
<td colspan="1" rowspan="1">~$8.1B</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~$8.2B</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic sales growth (1)</td>
<td colspan="1" rowspan="1">(4)% - 2%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(4)% - 2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Inorganic sales growth</td>
<td colspan="1" rowspan="1">~ 0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~ 0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Currency translation</td>
<td colspan="1" rowspan="1">~ (1.5)%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~ 0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported sales growth</td>
<td colspan="1" rowspan="1">(5.5)% - 0.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(4)% - 2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted EPS</td>
<td colspan="1" rowspan="1">$7.65 - $8.85</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$7.65 - $8.85</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS (1)</td>
<td colspan="1" rowspan="1">$8.60 - $9.80</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$8.60- $9.80</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Rockwell Automation 2025 Outlook Updated: Expects Sales Of ~$8.1B (Vs. $8.225B Est.) Prior $8.2B, And Sees Adjusted EPS Of $8.60-$9.80 (Vs. $9.40 Est.)

<h3>Gainers</h3>
<ul>
<li>Patriot Ntl Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNBK#NASDAQ">PNBK</a>) stock rose 91.7% to $2.78 during Monday's pre-market session. The company's market cap stands at $11.0 million. </li>
<li>Dominari Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>) stock increased by 19.56% to $3.85. The company's market cap stands at $24.1 million. </li>
<li>First Seacoast Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSEA#NASDAQ">FSEA</a>) stock moved upwards by 15.81% to $11.79. The market value of their outstanding shares is at $56.3 million. </li>
<li>Central Plains Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPBI#NASDAQ">CPBI</a>) stock moved upwards by 11.9% to $16.5. The market value of their outstanding shares is at $62.6 million. </li>
<li>DigiAsia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) shares rose 10.42% to $0.63. The market value of their outstanding shares is at $38.2 million. </li>
<li>Riverview Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSB#NASDAQ">RVSB</a>) stock rose 8.3% to $6.0. The company's market cap stands at $126.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Garden Stage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIW#NASDAQ">GSIW</a>) shares fell 18.3% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $10.0 million. </li>
<li>Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) shares declined by 14.57% to $6.51. The market value of their outstanding shares is at $571.3 million. </li>
<li>Powell Max (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMAX#NASDAQ">PMAX</a>) stock declined by 7.44% to $0.41. The market value of their outstanding shares is at $5.9 million. </li>
<li>Lion Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGHL#NASDAQ">LGHL</a>) stock declined by 7.33% to $0.15. The company's market cap stands at $3.4 million. </li>
<li>NBT Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>) stock declined by 6.45% to $45.42. The market value of their outstanding shares is at $2.1 billion. </li>
<li>Santech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) shares fell 6.2% to $0.65. The company's market cap stands at $18.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CPBI

DOMH

FAAS

FSEA

GSIW

LGHL

NBTB

PMAX

PNBK

RPAY

RVSB

STEC

12 Financials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) stock rose 30.9% to $25.0 during Monday's pre-market session. The market value of their outstanding shares is at $598.5 million. </li>
<li>Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) shares increased by 21.88% to $22.0. The market value of their outstanding shares is at $7.3 billion. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares rose 18.43% to $3.02. The market value of their outstanding shares is at $84.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 16.84% to $0.79. The market value of their outstanding shares is at $145.7 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares rose 12.74% to $0.49. The company's market cap stands at $9.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock increased by 12.5% to $3.24. The company's market cap stands at $129.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares declined by 57.6% to $3.3 during Monday's pre-market session. The company's market cap stands at $200.8 million. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) stock declined by 24.87% to $5.0. The market value of their outstanding shares is at $7.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock fell 19.59% to $11.21. The company's market cap stands at $862.6 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares decreased by 17.55% to $2.35. The company's market cap stands at $3.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 15.13% to $1.01. The market value of their outstanding shares is at $33.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock declined by 12.05% to $5.11. The market value of their outstanding shares is at $51.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Propel Funeral Partners

Propel Funeral Partners (OTC:PFPLF) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga